^
Association details:
| Biomarker: | EGFR exon 18-25 duplication |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Tagrisso (osimertinib) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Osimertinib is an effective epidermal growth factor receptor-tyrosine kinase inhibitor choice for lung cancer with epidermal growth factor receptor exon 18-25 kinase domain duplication: report of two cases
Published date:
07/12/2021
Excerpt:
...diagnosed with NSCLC including KDD....the osimertinib therapy achieved a stable disease state according to the chest computed tomography scan....osimertinib as an effective therapy for EGFR-KDD positive lung adenocarcinoma and thereby provide a new alternative for further treatment following resistance to first- and second-generation EGFR-TKIs.
DOI:
10.1097/CAD.0000000000001148
Source:
Title:
Durable response to EGFR tyrosine kinase inhibitors in a patient with non–small cell lung cancer harboring an EGFR kinase domain duplication
Published date:
07/09/2021
Excerpt:
...case of a 45-year-old Japanese woman with NSCLC positive for EGFR-KDD (duplication of exons 18–25) who developed carcinomatous meningitis and showed a marked response to the EGFR-TKIs erlotinib and osimertinib.
DOI:
https://doi.org/10.1111/1759-7714.14081
Test:
